EP1893575B1 - 2-(1h-indolylsulfanyl)-aryl amine derivatives - Google Patents

2-(1h-indolylsulfanyl)-aryl amine derivatives Download PDF

Info

Publication number
EP1893575B1
EP1893575B1 EP06808965.5A EP06808965A EP1893575B1 EP 1893575 B1 EP1893575 B1 EP 1893575B1 EP 06808965 A EP06808965 A EP 06808965A EP 1893575 B1 EP1893575 B1 EP 1893575B1
Authority
EP
European Patent Office
Prior art keywords
methyl
phenyl
ylsulfanyl
indol
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP06808965.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1893575A2 (en
Inventor
Jan Kehler
Karsten Juhl
Morten Bang Norgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of EP1893575A2 publication Critical patent/EP1893575A2/en
Application granted granted Critical
Publication of EP1893575B1 publication Critical patent/EP1893575B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to compounds of formula IV and the medical use thereof e.g. in the treatment of affective disorders, pain disorders, attention deficit hyperactivity disorder (ADHD) and stress urinary incontinence.
  • ADHD attention deficit hyperactivity disorder
  • the majority of currently available antidepressants can be classified in 3 classes:
  • 5-HT and/or NE-receptor blockers i.e. 5-HT and or NE-antagonist's
  • 5-HT and or NE-antagonist's have not proven very successful in the treatment of depression and anxiety and the preferred and currently most efficacious treatments are based on the enhancement of 5-HT and/or NE neurotransmission by blocking their reuptake back from the synaptic cleft ( Slattery, D.A. et al., "The evolution of antidepressant mechanisms", fundamental and Clinical pharmacology, 2004, 18, 1-21 ; Schloss, P. et al, "new insights into the mechanism of antidepressant therapy", Pharmacology and therapeutics, 2004, 102, 47-60 ).
  • SSRIs Selective serotonin reuptake inhibitors
  • Drugs claimed to be SSRIs are for example fluoxetine, sertraline and paroxetine.
  • Dual re-uptake inhibitors providing the combined effect of 5-HT reuptake inhibition and NE (norepinephrine is also named noradrenaline, NA) reuptake inhibition on depression is explored in clinical studies of compounds such as Duloxetine ( Wong, “Duloxetine (LY-248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate", Expert Opinion on Investigational Drugs, 1998, 7, 10, 1691-1699 ) and Venlafaxine ( Khan-A et al, 30 "Venlafaxine in depressed outpatients", Psychopharmacology Bulletin, 1991, 27, 141-144 ).
  • Compounds having such dual effect are also named SNRIs, “serotonin and noradrenaline reuptake inhibitors", or NSRIs, "noradrenaline and serotonin reuptake inhibitors”.
  • SNRI's have been shown in clinical studies to have a beneficial effect on pain (e.g. Fibromyalgia syndrome, overall pain, back pain, shoulder pain, headache, pain while awake and during daily activities) and especially pain associated with depression ( Berk, M. Expert Rev. Neurotherapeutics 2003, 3, 47-451 ; Fishbain, D.A., et al. "Evidence-based data from animal and human experimental studies on pain relief with antidepressants: A structured review" Pain Medicine 2000 1:310-316 ).
  • ADHD attention deficit hyperactivity disorder
  • Wellbutrin which has DA re-uptake activity in vitro and in vivo, shows antidepressant efficacy.
  • Other combination studies have indicated that addition of some affinity at the DA uptake site may have some clinical benefit ( Nelson, J. C. J. Clin. Psychiatry 1998, 59, 65 ; Masand, P. S. et al. Depression Anxiety 1998, 7, 89 ; Bodkin, J. A et al. J. Clin. Psychiatry 1997, 58, 137 ).
  • Diphenyl sulphides of formula I and variations thereof have been disclosed as serotonin re-uptake inhibitors and have been suggested for use in treatment of depression, cf. e.g. WO03029232(A1 ).
  • Diphenyl sulphides of formula II and variations thereof have been disclosed as serotonin re-uptake inhibitors and have been suggested for use in treatment of depression, cf. e.g. US 5095039 , US 4056632 , EP 396827 A1 and WO 9312080 .
  • EP 402097 describes halogen substituted diphenylsulfides claimed to be selective serotonin inhibitors for treatment of depression.
  • WO 9717325 disclose derivatives of N,N-dimethyl-2-(arylthio)benzylamine claimed to be selective serotonin transport inhibitors and suggest their use as antidepressants. J. Jilek et al., , Collect. Czeck Chem. Commun.
  • K. Sindelar et al. disclose compounds of formula III with test for selectivity as 5-HT re-uptake inhibitor and NA re-uptake inhibitor, respectively, for use as antidepressants.
  • the present invention provides 2-(1H-indolylsulfanyl)-aryl amine derivatives of formula IV which are serotonin reuptake inhibitors.
  • a particular aspect of the invention provides compounds possessing the combined effect of serotonin reuptake inhibition and norepinephrine reuptake inhibition.
  • Another particular aspect of the invention provides compounds possessing the combined effect of serotonin reuptake inhibition and dopamine reuptake inhibition.
  • some of the compounds are also triple 5-HT, NE and DA re-uptake inhibitors. wherein X, Y, Z, Q, m, n, o, p and R 1 -R 12 are as defined below.
  • One object of the invention is the provision of compounds, which are serotonin reuptake inhibitors. Another object of the invention is the provision of compounds, which are both serotonin reuptake inhibitors and noradrenaline reuptake inhibitors. Yet another object of the invention is the provision of compounds, which are both serotonin reuptake inhibitors and dopamine reuptake inhibitors. Yet another object of the invention is the provision of compounds, which are serotonin reuptake inhibitors, noradrenaline reuptake inhibitors and dopamine reuptake inhibitors.
  • the compounds of the invention are substituted indole derivatives of the general formula IV as the free base or salts thereof.
  • the invention provides a compound according to the above for use as a medicament.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound according to the above and at least one pharmaceutically acceptable carrier or diluent.
  • the invention provides the use of a compound according to the above for the preparation of a pharmaceutical composition for the treatment of affective disorders, pain disorders, ADHD and stress urinary incontinence.
  • the invention furthermore concerns the use of a compound according to the above in a method of treatment of affective disorders, pain disorders, ADHD and stress urinary incontinence.
  • heteroatom refers to a nitrogen, oxygen or sulphur atom.
  • Halo means halogen.
  • Halogen means fluoro, chloro, bromo or iodo.
  • C 1-6 -alk(en/yn)yl means a C 1-6 -alkyl, a C 2-6 -alkenyl or a C 2-6 -alkynyl group.
  • C 1-6 -alkyl refers to a branched or unbranched alkyl group having from one to six carbon atoms inclusive, including but not limited to methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl and 2-methyl-1-propyl.
  • C 2-6 -alkenyl refers to a branched or unbranched alkenyl group having from two to six carbon atoms, including one double bond, including but not limited to ethenyl, propenyl, and butenyl.
  • C 2-6 -alkynyl refers to a branched or unbranched alkynyl group having from two to six carbon atoms, including one triple bond, including but not limited to ethynyl, propynyl and butynyl.
  • C 3-8 -cycloalk(en)yl means a C 3-8 -cycloalkyl or a C 3-8 -cycloalkenyl group.
  • C 3-8 -cycloalkyl designates a monocyclic or bicyclic carbocycle having three to eight C-atoms, including but not limited to cyclopropyl, cyclopentyl, and cyclohexyl.
  • C 3-8 -cycloalkenyl designates a monocyclic or bicyclic carbocycle having three to eight C-atoms and one double bond, including but not limited to cyclopropenyl, cyclopentenyl and cyclohexenyl.
  • R 1 and R 2 together with the nitrogen form a 4-7 membered ring containing zero or one double bond, optionally said ring in addition to said nitrogen comprises one further heteroatom selected from oxygen and sulphur refers to such ring systems wherein a ring is formed by the nitrogen to which R 1 and R 2 are attached and 3-6 atoms selected from 2-6 carbonatoms and 0-1 heteroatoms selected from sulphur and oxygen, said ring contains zero or one double bond.
  • rings formed by R 1 , R 2 and the nitrogen to which they are attached are pyrrolidine, piperidine, morpholine and thiomorpholine..
  • the present invention relates to a compound represented by the general formula IV wherein
  • R 1 and R 2 are independently selected from the group consisting of C 3-8 -cycloalk(en)yl and C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl.
  • R 1 and R 2 are independently selected from the group consisting of hydrogen and C 1-6 -alk(en/yn)yl; or R 1 and R 2 together with the nitrogen form a 4-7 membered ring containing zero or one double bond, optionally said ring in addition to said nitrogen comprises one further heteroatom selected from oxygen and sulphur.
  • R 1 is hydrogen; another embodiment of R 1 is C 1-6 -alk(en/yn)yl such as methyl.
  • R 2 is hydrogen; another embodiment of R 2 is C 1-6 -alk(en/yn)yl such as methyl.
  • an embodiment of the compound of formula IV concerns such compounds wherein R 1 and R 2 together with the nitrogen form a 4-7 membered ring containing zero or one double bond, optionally said ring in addition to said nitrogen comprises one further heteroatom selected from oxygen and sulphur.
  • said 4-7 membered ring does not contain any double bond; in another embodiment said 4-7 membered ring does contain one double bond.
  • the only heteroatom contained in said 4-7 membered ring is the nitrogen to which R 1 and R 2 are attached.
  • said 4-7 membered ring contains one heteroatom in addition to the nitrogen to which R 1 and R 2 are attached; in a further embodiment said heteroatom is sulphur; in a further embodiment said heteroatom is oxygen.
  • said 4-7 membered ring is selected from the group consisting of morpholine and thiomorpholine.
  • R 3 -R 6 and R 8 -R 12 are independently selected from the group consisting of C 1-6 -alk(en/yn)ylcarbonyl, aminocarbonyl, C 1-6 -alk(en/yn)ylaminocarbonyl, di-(C 1-6 -alk(en/yn)yl)aminocarbonyl and hydroxy.
  • R 3 -R 6 and R 8 -R 12 are independently selected from the group consisting of hydrogen, halogen, cyano, nitro, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, amino, C 1-6 -alk(en/yn)ylamino, amino, C 1-6 -alk(en/yn)yloxy, C 1-6 -alk(en/yn)ylsulfanyl, halo-C 1-6 -alk(en/yn)yl, halo-C 1-6 -alk(en/yn)ylsulfonyl, halo-C 1-6 -alk(en/yn)ylsulfanyl and C 1-6 -alk(en/yn)yl
  • R 3 -R 6 and R 8 -R 12 are independently selected from the group consisting of hydrogen, halogen, C 1-6 -alk(en/yn)yl, and C 1-6 -alk(en/yn)yloxy.
  • R 3 -R 6 are independently selected from the group consisting of nitro, amino, C 1-6 -alk(en/yn)ylamino, di-(C 1-6 -alk(en/yn)yl)amino, C 1-6 -alk(en/yn)ylcarbonyl, aminocarbonyl, C 1-6 -alk(en/yn)ylaminocarbonyl, di-(C 1-6 -alk(en/yn)yl)aminocarbonyl, hydroxy, halo-C 1-6 -alk(en/yn)ylsulfonyl and C 1-6 -alk(en/yn)ylsulfonyl.
  • R 3 -R 6 are independently selected from the group consisting of hydrogen, halogen, cyano, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, halo-C 1-6 -alk(en/yn)yl, C 1-6 -alk(en/yn)yloxy, C 1-6 -alk(en/yn)ylsulfanyl and halo-C 1-6 -alk(en/yn)ylsulfanyl.
  • R 3 -R 6 are independently selected from the group consisting of hydrogen, halogen and C 1-6 -alk(en/yn)yloxy.
  • R 3 is hydrogen.
  • R 4 is selected from the group consisting of hydrogen, halogen and C 1-6 -alk(en/yn)yloxy.
  • an embodiment of R 4 is hydrogen; another embodiment of R 4 is halogen such as chloro or fluoro; another embodiment of R 4 is C 1-6 -alk(en/yn)yloxy such as methoxy.
  • R 5 is selected from the group consisting of hydrogen and C 1-6 -alk(en/yn)yloxy.
  • an embodiment of R 5 is hydrogen; another embodiment of R 5 is C 1-6 -alk(en/yn)yloxy such as methoxy.
  • an embodiment of R 6 is hydrogen.
  • R 8 -R 12 are independently selected from the group consisting of C 1-6 -alk(en/yn)ylcarbonyl, aminocarbonyl, C 1-6 -alk(en/yn)ylaminocarbonyl, di-(C 1-6 -alk(en/yn)yl)aminocarbonyl and hydroxy.
  • R 8 -R 12 are independently selected from the group consisting of hydrogen, halogen, cyano, nitro, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, amino, C 1-6 -alk(en/yn)ylamino, di-(C 1-6 -alk(en/yn)yl)amino, C 1-6 -alk(en/yn)yloxy, C 1-6 -alk(en/yn)ylsulfanyl, halo-C 1-6 -alk(en/yn)yl, halo-C 1-6 -alk(en/yn)ylsulfonyl, halo-C 1-6 -alk(en/yn)ylsulfanyl and C
  • R 8 -R 12 are independently selected from the group consisting of hydrogen, halogen, C 1-6 -alk(en/yn)yl and C 1-6 -alk(en/yn)yloxy.
  • R 8 is selected from the group consisting of hydrogen, halogen and C 1-6 -alk(en/yn)yloxy.
  • an embodiment of R 8 is hydrogen; another embodiment of R 8 is halogen such as chloro or fluoro; another embodiment of R 8 is C 1-6 -alk(en/yn)yloxy such as methoxy.
  • R 9 is selected from the group consisting of hydrogen, halogen, C 1-6 -alk(en/yn)yl and di-(C 1-6 -alk(en/yn)yl)amino.
  • an embodiment of R 9 is hydrogen; another embodiment of R 9 is halogen such as chloro or fluoro; another embodiment of R 9 is C 1-6 -alk(en/yn)yl such as methyl; another embodiment of R 9 is di-(C 1-6 -alk(en/yn)yl)amino such as dimethylamino.
  • R 10 is selected from the group consisting of hydrogen, halogen and C 1-6 -alk(en/yn)ylsulfonyl.
  • R 10 is hydrogen; another embodiment of R 10 is halogen such as fluoro; another embodiment of R 10 is C 1-6 -alk(en/yn)ylsulfonyl such as methylsulfonyl.
  • R 11 is selected from the group consisting of hydrogen, halogen, nitro and C 1-6 -alk(en/yn)yloxy.
  • R 11 is hydrogen; another embodiment of R 11 is halogen such as chloro or fluoro; another embodiment of R 11 is nitro; another embodiment of R 11 is C 1-6 -alk(en/yn)yloxy such as methoxy.
  • R 12 is selected from the group consisting of hydrogen and C 1-6 -alk(en/yn)yl.
  • an-embodiment of R 12 is hydrogen; another embodiment of R 12 is C 1-6 -alk(en/yn)yl such as methyl.
  • R 7 is selected from the group consisting of C 3-8 -cycloalk(en)yl and C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl.
  • R 7 is selected from the group consisting of hydrogen and C 1-6 -alk(en/yn)yl.
  • an embodiment of R 7 is hydrogen; another embodiment of R 12 is C 1-6 -alk(en/yn)yl such as methyl.
  • X is selected from the group consisting of CHR 13 and CR 14 R 15
  • Y is selected from the group consisting of CHR 16 and CR 17 R 18
  • Z is selected from the group consisting of CHR 19 and CR 20 R 21
  • Q is selected from the group consisting of CHR 22 and CR 23 R 24 .
  • X, Y, Z and Q are CH 2 .
  • m+ n + o + p equals to 1, 2, 3 or 4; in another embodiment of formula IV, m+ n + o + p equals to 1; in another embodiment of formula IV, m+ n + o + p equals to 2; in another embodiment of formula IV, m+ n + o + p equals to 3; in another embodiment of formula IV, m+ n + o + p equals to 4.
  • said compound is selected from the following list of compounds: Compound No Name 1 ⁇ 2-[5-Fluoro-2-(1H-indol-3-ylsulfanyl)-phenyl]-ethyl ⁇ -methyl-amine 2 ⁇ 2-[2-(6-Fluoro-1H-indol-3-ylsulfanyl)-phenyl]-ethyl ⁇ -methyl-amine 3 ⁇ 2-[2-(5-Fluoro-1H-indol-3-ylsulfanyl)-phenyl]-ethyl ⁇ -methyl-amine 4 ⁇ 2-[2-(4-Fluoro-1H-indol-3-ylsulfanyl)-phenyl]-ethyl ⁇ -methyl-amine 5 ⁇ 2-[2-(7-Fluoro-1H-indol-3-ylsulfanyl)-phenyl]-ethyl ⁇ -methyl-amine
  • the present invention comprises the free base and salts of the compounds of the invention, typically, pharmaceutically acceptable salts.
  • the salts of the invention include acid addition salts, metal salts, ammonium and alkylated ammonium salts.
  • the salts of the invention are preferably acid addition salts.
  • the acid addition salts of the invention are preferably pharmaceutically acceptable salts of the compounds of the invention formed with non-toxic acids.
  • Acid addition salts include salts of inorganic acids as well as organic acids. Examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, sulfamic, nitric acids and the like.
  • suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, theophylline acetic acids, as well as the 8-alotheophyllines, for example 8-bromotheophylline and the like
  • metal salts examples include lithium, sodium, potassium, magnesium salts and the like.
  • ammonium and alkylated ammonium salts include ammonium, methyl-, dimethyl-, trimethyl-, ethyl-, hydroxyethyl-, diethyl-, n-butyl-, sec-butyl-, tert-butyl-, tetramethylammonium salts and the like.
  • the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like.
  • the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
  • the compounds of the present invention may have one or more asymmetric centre and it is intended that any optical isomers (i.e. enantiomers or diastereomers), as separated, pure or partially purified optical isomers and any mixtures thereof including racemic mixtures, i.e. a mixture of stereoisomeres, are included within the scope of the invention.
  • any optical isomers i.e. enantiomers or diastereomers
  • pure or partially purified optical isomers i.e. a mixture of stereoisomeres
  • Racemic forms can be resolved into the optical antipodes by known methods, for example, by separation of diastereomeric salts thereof with an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix. Racemic compounds of the present invention can also be resolved into their optical antipodes, e.g. by fractional crystallization. The compounds of the present invention may also be resolved by the formation of diastereomeric derivatives. Additional methods for the resolution of optical isomers, known to those skilled in the art, may be used. Such methods include those discussed by J. Jaques, A. Collet and S. Wilen in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981 ). Optically active compounds can also be prepared from optically active starting materials, or by stereoselective synthesis.
  • geometric isomers may be formed. It is intended that any geometric isomers, as separated, pure or partially purified geometric isomers or mixtures thereof are included within the scope of the invention. Likewise, molecules having a bond with restricted rotation may form geometric isomers. These are also intended to be included within the scope of the present invention.
  • the invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming pharmacologically active substances.
  • prodrugs will be functional derivatives of the compounds of the general formula IV which are readily convertible in vivo into the required compound of the formula IV.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in " Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985 .
  • the invention also encompasses active metabolites of the present compounds.
  • Some compounds according to the invention inhibit the serotonin transporter and are thus serotonin reuptake inhibitors.
  • the compounds have an in vitro uptake inhibition (IC50) of 5 ⁇ M or less, typically of 1 ⁇ M or less, preferably less than 500nM or less than 100 nM or less than 50 nM, preferably as measured by the method described in Example 13 - Measurements of "[ 3 H]-5-HT uptake into rat cortical synaptosomes".
  • Some compounds according to the invention inhibit the norepinephrine transporter and are thus norepinephrine reuptake inhibitors.
  • the compounds typically have an in vitro uptake inhibition (IC50) of 5 ⁇ M or less, typically of 1 ⁇ M or less, preferably less than 500nM, less than 100 nM or less than 50 nM, as measured by the method described in Example 13 - Measurements of "[ 3 H]noradrenaline uptake into rat cortical synaptosomes".
  • Some compounds according to the invention inhibit the dopamine transporter and are thus dopamine reuptake inhibitors.
  • such compounds have an in vitro uptake inhibition (IC50) of 5 ⁇ M or less, typically of 1 ⁇ M or less, preferably less than 500nM, less than 100 nM or less than 50 nM, preferably as measured by the method described in Example 13 - "Measurements of [ 3 H]dopamine uptake into rat cortical synaptosomes".
  • the compounds according to the invention are serotonin reuptake inhibitors and-they are thus considered to be applicable in the treatment of one or more of the following diseases/disorders: affective disorders, pain disorders, ADHD and stress urinary incontinence.
  • An embodiment concerns compounds of the invention having dual action, said compounds being serotonin reuptake inhibitors and norepinephrine reuptake inhibitors at the same time.
  • such compounds have an in vitro uptake inhibition for the serotonin transporter which is at least 1, typically at least 5 or even more typically at least 10, 20 or 30 times higher than the in vitro uptake inhibition for the norepinephrine transporter as measured by the methods described in Example 13 - "Measurements of [ 3 H]-5-HT uptake into rat cortical synaptosomes" and “Measurements of [ 3 H]noradrenaline uptake into rat cortical synaptosomes".
  • An embodiment concerns compounds of the invention having dual action, said compounds being serotonin reuptake inhibitors and dopamine reuptake inhibitors at the same time.
  • such compounds have an in vitro uptake inhibition for the serotonin transporter which is at least 1, typically at least 5 or even more typically at least 10, 20 or 30 times higher than the in vitro uptake inhibition for the dopamine transporter as measured by the methods described in Example 13 - "Measurements of [ 3 H]-5-HT uptake into rat cortical synaptosomes" and “Measurements of [ 3 H]dopamine uptake into rat cortical synaptosomes".
  • a further embodiment concerns compounds of the invention having triple action and thus being serotonin reuptake inhibitors, norepinephrine reuptake inhibitors and dopamine reuptake inhibitors.
  • the invention provides a compound of formula IV as the free base or a salt thereof for use as a medicament.
  • An embodiment of the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula IV as the free base or a salt thereof and at least one pharmaceutically acceptable carrier or diluent.
  • the composition may comprise any one of the embodiments of formula IV described above.
  • a further embodiment of the invention relates to the use of a compound of formula IV as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of a disease or disorder wherein a serotonin reuptake inhibitor is beneficial.
  • Such pharmaceutical composition may comprise any one of the embodiments of formula IV described above.
  • a further embodiment of the invention relates to the use of a compound of formula IV as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of a disease or disorder, wherein a combined serotonin and norepinephrine reuptake inhibitor is beneficial.
  • Such pharmaceutical composition may comprise any one of the embodiments of formula IV described above.
  • a further embodiment of the invention relates to the use of a compound of formula IV as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of a disease or disorder, wherein a combined serotonin and dopamine reuptake inhibitor is beneficial.
  • Such pharmaceutical composition may comprise any one of the embodiments of formula IV described above.
  • a further embodiment of the present invention relates to the use of a compound of formula IV as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of a disease or disorder, wherein a combined serotonin, norepinephrine and dopamine reuptake inhibitor is beneficial.
  • Such pharmaceutical composition may comprise any one of the embodiments of formula IV described above.
  • a further embodiment of the invention relates to the use of a compound of formula IV as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of affective disorders, pain disorders, ADHD and stress urinary incontinence.
  • the present invention relates to the use of a compound of formula IV as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of affective disorders.
  • the affective disorder to be treated is selected from the group consisting of depressive disorders and anxiety disorders:
  • a further embodiment concerns the use of a compound of formula IV as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of anxiety disorders.
  • the anxiety disorders to be treated are selected from the group consisting of general anxiety disorder, social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, panic disorder, panic attacks, specific phobias, social phobia and agoraphobia.
  • the present invention relates to the use of a compound of formula IV as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of pain disorders.
  • the pain disorder to be treated is selected from the group consisting of fibromyalgia syndrome (FMS), overall pain, back pain, shoulder pain, headache as well as pain while awake and during daily activities.
  • FMS fibromyalgia syndrome
  • the present invention relates to the use of a compound of formula IV as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of attention deficit hyperactivity disorder.
  • the present invention relates to the use of a compound of formula IV as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of stress urinary incontinence.
  • the present invention relates to a method of preparing a compound of formula IV, comprising the nucleophilic substitution reaction of appropriately substituted indoles and appropriately substituted benzene sulfenyl chlorides.
  • treatment as used herein in connection with a disease or disorders includes also prevention as the case may be.
  • the present invention also relates to a pharmaceutical composition.
  • the compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents, in either single or multiple doses.
  • the pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19 Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995 .
  • compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.
  • compositions formed by combining the compound of the invention and the pharmaceutical acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration.
  • the formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.
  • the compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof.
  • One example is an acid addition salt of a compound having the utility of a free base.
  • a compound of the invention contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of the invention with a chemical equivalent of a pharmaceutically acceptable acid. Representative examples are mentioned above.
  • compositions for oral administration may be solid or liquid.
  • Solid dosage forms for oral administration include e.g. capsules, tablets, dragees, pills, lozenges, powders, granules and tablette e.g. placed in a hard gelatine capsule in powder or pellet form or e.g. in the form of a troche or lozenge.
  • pharmaceutical compositions for oral administration may be prepared with coatings such as enteric coatings or they can be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well known in the art.
  • Liquid dosage forms for oral administration include e.g. solutions, emulsions, suspensions, syrups and elixirs.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient.
  • the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.
  • Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents.
  • solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid, lower alkyl ethers of cellulose, corn starch, potato starch, gums and the like.
  • liquid carriers are syrup, peanut oil, olive oil, phospho lipids, fatty acids, fatty acid amines, polyoxyethylene and water.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • any adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.
  • the amount of solid carrier may vary but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tabletting machine.
  • compositions for parenteral administration include sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also contemplated as being within the scope of the present invention.
  • solutions of the compound of the invention in sterile aqueous solution aqueous propylene glycol, aqueous vitamin E or sesame or peanut oil may be employed.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • the aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to the desired volume, sterilising the solution and filling it in suitable ampoules or vials.
  • Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.
  • Suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants, etc.
  • a typical oral dosage is in the range of from about 0.001 to about 100 mg/kg body weight per day, preferably from about 0.01 to about 50 mg/kg body weight per day, and more preferred from about 0.05 to about 10 mg/kg body weight per day administered in one or more dosages such as 1, 2 or 3 dosages.
  • the exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and-severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.
  • a typical unit dosage form for oral administration one or more times per day such as 1, 2 or 3 times per day may contain from 0.01 to about 1000 mg, such as about 0.01 to 100 mg, preferably from about 0.05 to about 500 mg, and more preferred from about 0.5 mg to about 200 mg.
  • parenteral routes such as intravenous, intrathecal, intramuscular and similar administration
  • typically doses are in the order of about half the dose employed for oral administration.
  • Typical examples of recipes for the formulation of the invention are as follows: 1) Tablets containing 5.0 mg of a compound of the invention calculated as the free base: Compound of the invention 5.0 mg Lactose 60 mg Maize starch 30 mg Hydroxypropylcellulose 2.4 mg Microcrystalline cellulose 19.2 mg Croscarmellose Sodium Type A 2.4 mg Magnesium stearate 0.84 mg 2) Tablets containing 0.5 mg of a compound of the invention calculated as the free base: Compound of the invention 0.5 mg Lactose 46.9 mg Maize starch 23.5 mg Povidone 1.8 mg Microcrystalline cellulose 14.4 mg Croscarmellose Sodium Type A 1.8 mg Magnesium stearate 0.63 mg 3) Syrup containing per millilitre: Compound of the invention 25 mg Sorbitol 500 mg Hydroxypropylcellulose 15 mg Glycerol 50 mg Methyl-paraben 1 mg Propyl-paraben 0.1 mg Ethanol 0.005 mL Flavour 0.05 mg Saccharin sodium
  • a compound of the invention is meant any one of the embodiments of formula IV as described herein.
  • the present invention relates to a method of preparing a compound of the invention as described in the following.
  • Indoles of formula V are either commercially available or can be prepared according to methods described in standard works such as Houben-Weyl, Methoden der organischen Chemie (Methods of Organic Chemistry), Georg-Thieme-Verlag, Stuttgart ; Organic Reactions, John Wiley & Sons, Inc. New York , namely under reaction conditions such as those which are known as suitable for such reactions.
  • R 1 -R 12 , X, Y, Z, Q, m, n, o, p are as defined herein
  • PG is a nitrogen protecting group
  • SPG is a thiol protecting group, e.g. a tri- iso -propyl silyl group
  • R 25 is a halogen such as iodine or bromine or R 25 is a pseudo halogen such as e.g. a trifluoro methyl sulphonyl group or a nonafluoro butyl sulphonyl group.
  • R 1 -R 6 , R 22 X, Y, Z, m, n, o are as defined herein and R 25 is a halogen such as iodine or bromine or R 25 is a pseudo halogen such as e.g. a trifluoro methyl sulphonyl group or a nonafluoro butyl sulphonyl group.
  • 1-Bromo-2-iodobenzene compounds of formula XXIII, olefins of formula XXIV or of formula XXV are commercially available or can be prepared according to methods described in standard works such as Houben-Weyl, Methoden der organischen Chemie (Methods of Organic Chemistry), Georg-Thieme-Verlag, Stuttgart ; Organic Reactions, John Wiley & Sons, Inc. New York , namely under reaction conditions such as those which are known as suitable for such reactions.
  • R 25 is a halogen such as iodine or bromine or R 25 is a pseudo halogen such as e.g. a trifluoro methyl sulphonyl group or a nonafluoro butyl sulphonyl group.
  • Analytical LC-MS data were obtained on a PE Sciex API 150EX instrument equipped with atmospheric pressure photo ionisation and a Shimadzu LC-8A/SLC-10A LC system.
  • Method Linear gradient elution with 90% A/10% B to 100% B in 4 minutes and with a flow rate of 2 mL/minute. Purity was determined by integration of the UV (254 nm) and ELSD trace.
  • t R The retention times (t R ) are expressed in minutes.
  • Preparative LC-MS-purification was performed on the same instrument with atmospheric pressure chemical ionisation. Column: 50 X 20 mm YMC ODS-A with 5 ⁇ m particle size; Method: Linear gradient elution with 80% A to 100% B in 7 minutes and with a flow rate of 22.7 mL/minute. Fraction collection was performed by split-flow MS detection.
  • Method Linear gradient elution with 90% A/10% B to 100% B in 4 minutes and with a flow rate of 2 mL/minute. Purity was determined by integration of the UV (254 nm) and ELSD trace. The retention times (t R ) are expressed in minutes.
  • the mixture is stirred for 15 minutes at 0°C before adding saturated sodium bicarbonate solution (15 mL).
  • the mixture is extracted with ethyl acetate (3 x 20 mL) and the combined organic fractions are washed with brine, dried (MgSO 4 ) and concentrated in vacuo.
  • the product is purified by silica gel chromatography eluting with ethyl acetate-heptane, first (1:10) then (1:4). Upon evaporation of the volatiles 99 mg (29%) of the title compound is isolated.
  • reaction vessel is sealed and subjected to microwave heating at 160°C for 15 minutes. Upon cooling the mixture is poured onto a plug of silica and the product is eluted with ethyl acetate-heptane (1:10). This furnishes 1.6 g (40%) of the title compound as an oil, which is used in the next step without further purification.
  • Lithium aluminum hydride (7.50 g, 197 mmol) is suspended in dry diethyl ether (75 mL) and cooled to 0°C.
  • Aluminum (III) chloride (8.80g, 65.8 mmol) dissolved in dry diethyl ether (75 mL) is added dropwise at 0-5°C.
  • the cooling bath is removed and the mixture is stirred at ambient temperature for 1 hour.
  • the resulting aluminum hydride reagent solution is cooled to 0°C followed by dropwise addition of 2-(2-bromo-5-fluoro-phenyl)-N-methyl-acetamide (16.2 g, 65.8 mmol) dissolved in dry THF (150 mL). After complete addition the solution is allowed to heat to ambient temperature and stirring is continued for 16 hours.
  • Methyl amine (8M in ethanol, 38 mL, 304 mmol) is added to 3-(2-bromo-phenyl)-propionaldehyde (6.32 g, 29.7 mmol) and sodium cyanoborohydride (2.24 g, 35.6 mmol) in methanol.
  • the reaction mixture is cooled to 0°C and acetic acid is added slowly until pH ⁇ 7.
  • the reaction mixture is stirred for 1 ⁇ 2 hour and neutralized with aqueous sodium hydroxide.
  • Methanol is removed in vacuo and ethyl acetate and brine are added.
  • the aqueous phase is extracted with ethyl acetate and the combined organic phases are dried with MgSO 4 and concentrated in vacuo.
  • N,N '-Dicyclohexylcarbodiimide (875 mg, 4.2 mmol) is added to [2-(1H-Indol-3-ylsulfanyl)-phenyl]-acetic acid (600 mg, 2.1 mmol) in 3 mL dry DMF and 7 mL acetonitril and stirred for 10 minutes hours at room temperature. 5.3 mL dimethyl amine (2M in THF, 10.6 mmol) is added and the reaction mixture is stirred 16 hours at room temperature. The reaction mixture is concentrated in vacuo. The residue is extracted with ethyl acetate (3 times). The combined orgnic phases are washed with brine, dried with MgSO 4 and concentrated in vacuo. Purification by flash chromatography on silica gel (ethyl acetate/heptane) gives 116 mg (18%) of the title compound.
  • Methanesulfonyl chloride (7.7 mL, 97 mmol) in 100 mL dry THF is added to a solution of 3-(2-bromo-phenyl)-propan-1-ol (17.4 g, 80.9 mmol) and triethyl amine (14.7 g, 146 mmol) in 200 mL dry THF at 0°C under an argon atmosphere. Water is added and the mixture is extracted with ethyl acetate. The organic phase is washed with brine, dried with MgSO 4 and concentrated in vacuo to give 23 g (97%) methanesulfonic acid 3-(2-bromo-phenyl)-propyl ester as an oil.
  • Methanesulfonic acid 3-(2-bromo-phenyl)-propyl ester (23g, 78 mmol) in 300 mL dry DMF is added to a suspension of potassium cyanide (15.3 g, 235 mmol) in dry DMF.
  • the reaction mixture is stirred at 60°C for 16 hours. Water is added and the mixture is extracted with ethyl acetate (3 times). The organic phase is washed with brine (twice), dried with MgSO 4 and concentrated in vacuo.
  • composition of assay buffer 123 mM NaCl, 4.82 mM KCl, 0.973 mM CaCl 2 , 1.12 mM MgSO 4 , 12.66 mM Na 2 HPO 4 , 2.97 mM NaH 2 PO 4 , 0.162 mM EDTA, 2g/l glucose and 0,2g/l ascorbic acid.
  • Buffer is oxygenated with 95% 0 2 /5% CO 2 for 10 min. The incubation is started by adding tissue to a final assay volume of 0.2 mL.
  • Fresh occipital-, temporal- or parietal cortex from male Wistar rats (125-225 g) are homogenized in 0.4M sucrose with a glass/teflon homogenizer. The homogenate is centrifuged at 1000 x g for 10 min at 4 °C. The pellet is discarded and the supernatant is centrifuged at 40.000 x g for 20 min.
  • the buffer is oxygenated with 95% 0 2 /5% CO 2 for 10 min.
  • the pellet is suspended in 140 volumes of assaybuffer.
  • Tissue is mixed with test compounds and after 10 min pre-incubation, 10 nM [ 3 H]-noradrenaline is added to a final volume of 0,2 ml and the mixture is incubated for 15 min at 37°C. After 15 min incubation, samples are filtered directly on Unifilter GF/C glass fiber filters (soaked for 30 min in 0.1 % polyethylenimine) under vacuum and immediately washed with 1 x 0,2 mL assay buffer.
  • Non-specific uptake is determined using talsupram (10 ⁇ M final concentration). Duloxetine is included as reference in all experiments as dose-response curve.
  • Tissue preparation male wistar rats (125-250 g) are sacrificed by decapitation and striatum quickly dissected out and placed in ice cold 0,40 M sucrose. The tissue is gently homogenised (glass teflon homogeniser) and the P2 fraction is obtained by centrifugation (1000 g, 10 minutes and 40000 g, 20 minutes, 4°C) and suspended in 560 volumes of a modified Krebs-Ringer-phosphate buffer, pH 7.4.
  • Tissue 0,25 mg/well(140 ⁇ l) (original tissue) is mixed with test suspension. After 5 minutes pre-incubation at room temperature, 12.5 nM [ 3 H ]-dopamine is added and the mixture is incubated for 5 minutes at room temperature. Final volume is 0,2 mL.
  • the incubation is terminated by filtering the samples under vacuum through Whatman GF/C filters with a wash of 1 x 0,2ml buffer.
  • the filters are dried and appropriate scintillation fluid (Optiphase Supermix) is added.
  • Optiphase Supermix appropriate scintillation fluid
  • Uptake is obtained by subtracting the non-specific binding and passive transport measured in the presence of 100 ⁇ M of benztropin. For determination of the inhibition of uptake ten concentrations of drugs covering 6 decades are used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP06808965.5A 2005-06-17 2006-06-14 2-(1h-indolylsulfanyl)-aryl amine derivatives Active EP1893575B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69200905P 2005-06-17 2005-06-17
PCT/IB2006/002785 WO2006134499A2 (en) 2005-06-17 2006-06-14 2-(1h-indolylsulfanyl)-aryl amine derivatives

Publications (2)

Publication Number Publication Date
EP1893575A2 EP1893575A2 (en) 2008-03-05
EP1893575B1 true EP1893575B1 (en) 2017-01-11

Family

ID=37532681

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06808965.5A Active EP1893575B1 (en) 2005-06-17 2006-06-14 2-(1h-indolylsulfanyl)-aryl amine derivatives

Country Status (15)

Country Link
EP (1) EP1893575B1 (enExample)
JP (1) JP5144507B2 (enExample)
KR (1) KR20080027462A (enExample)
CN (1) CN101238101A (enExample)
AR (1) AR054394A1 (enExample)
AU (1) AU2006257288A1 (enExample)
BR (1) BRPI0611748A2 (enExample)
CA (1) CA2611566C (enExample)
EA (1) EA200800070A1 (enExample)
ES (1) ES2616095T3 (enExample)
IL (1) IL188064A0 (enExample)
MX (1) MX2007014954A (enExample)
NO (1) NO20080265L (enExample)
WO (1) WO2006134499A2 (enExample)
ZA (1) ZA200710885B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100286226A1 (en) * 2007-09-24 2010-11-11 H. Lundbeck A/S Combination therapy related to serotonin dual action compounds
TW200938189A (en) * 2008-03-13 2009-09-16 Lundbeck & Co As H [2-(6-flouro-1H-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders
US9000025B2 (en) 2010-08-20 2015-04-07 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
ES2687481T3 (es) * 2013-03-15 2018-10-25 Chromocell Corporation Moduladores del canal de sodio para el tratamiento del dolor
EP3046909A4 (en) 2013-09-17 2017-03-29 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
US9714240B2 (en) 2013-09-17 2017-07-25 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
JP2016531874A (ja) 2013-09-26 2016-10-13 ファーマケア，インク． オートタキシン阻害剤化合物
CA2930737C (en) 2013-11-22 2023-02-21 Pharmakea, Inc. Autotaxin inhibitor compounds
SG10201911204WA (en) 2015-05-27 2020-02-27 Pharmakea Inc Autotaxin inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117129A (en) * 1976-10-22 1978-09-26 Warner-Lambert Company Indolobenzoxazepines as cns depressants
ES2128281T1 (es) * 1995-11-06 1999-05-16 Gist Brocades Bv Proceso de desesterificacion.
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
JP4090491B2 (ja) * 2003-12-23 2008-05-28 ハー・ルンドベック・アクチエゼルスカベット ２−（１ｈ−インドリルスルファニル）−ベンジルアミン誘導体
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto

Also Published As

Publication number Publication date
MX2007014954A (es) 2008-02-15
EP1893575A2 (en) 2008-03-05
WO2006134499A2 (en) 2006-12-21
JP5144507B2 (ja) 2013-02-13
ZA200710885B (en) 2009-03-25
BRPI0611748A2 (pt) 2016-11-22
AR054394A1 (es) 2007-06-20
NO20080265L (no) 2008-01-15
JP2008546679A (ja) 2008-12-25
ES2616095T3 (es) 2017-06-09
IL188064A0 (en) 2008-03-20
CN101238101A (zh) 2008-08-06
AU2006257288A1 (en) 2006-12-21
KR20080027462A (ko) 2008-03-27
EA200800070A1 (ru) 2008-04-28
WO2006134499A3 (en) 2007-04-12
CA2611566A1 (en) 2006-12-21
CA2611566C (en) 2011-08-16

Similar Documents

Publication Publication Date Title
US7737171B2 (en) Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS
EP1893575B1 (en) 2-(1h-indolylsulfanyl)-aryl amine derivatives
EP1771415B1 (en) 2- (1h-indolylsulfanyl) -aryl amine derivatives for use in the treatment of affective disorders, pain, adhd and stress urinary incontinence
US7629473B2 (en) 2-(1H-indolylsulfanyl)-aryl amine derivatives
US20090192213A1 (en) Benzo[b]furane And Benzo[b]thiophene Derivatives
EP1860100B1 (en) 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI
HK1120496A (en) 2-(1h-indolylsulfanyl)-aryl amine derivatives
HK1119674A (en) Benzo[b]furane and benzo[b]thiophene derivatives
HK1103075B (en) 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080117

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20080117

Extension state: MK

Payment date: 20080117

Extension state: AL

Payment date: 20080117

Extension state: RS

Payment date: 20080117

Extension state: BA

Payment date: 20080117

17Q First examination report despatched

Effective date: 20140207

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160307

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NORGAARD, MORTEN BANG

Inventor name: JUHL, KARSTEN

Inventor name: KEHLER, JAN

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: H. LUNDBECK A/S

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 861134

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006051524

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170111

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2616095

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170609

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 861134

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170511

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170412

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170411

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170511

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006051524

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

26N No opposition filed

Effective date: 20171012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170614

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170614

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20060614

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20190604

Year of fee payment: 14

Ref country code: IT

Payment date: 20190620

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20190510

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170111

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20190612

Year of fee payment: 14

Ref country code: ES

Payment date: 20190701

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170111

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006051524

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200615